SLCTR_2011_008
BI 10773 Cardiovascular Outcomes Trial in Type 2 Diabetes Mellitus Patients
A Phase III, multicentre, international, randomised, parallel group, double blind cardiovascular safety study of BI 10773 (10 mg and 25 mg administered orally once daily) compared to usual care in type 2 diabetes mellitus patients with increased cardiovas
Boehringer Ingelheim India Pvt LtdPhase 3Sri Lanka Clinical Trials Registry
VerifiedSri Lanka Clinical Trials Registry
Study focus
- Disease/Condition
- Diabetes Mellitus, Type 2
- Study type
- Interventional
Sponsor & location
- Primary sponsor
- Boehringer Ingelheim India Pvt Ltd
- Location
- Argentina, Austria, Belgium, Brazil, Canada, Colombia, Croatia, Denmark, France, Georgia, Greece, Hu
Timeline & enrollment
- Phase
- Phase 3
- Start date
- N/A
- End date
- N/A
ICD-10 classifications
Type 2 diabetes mellitusType 2 diabetes mellitus with unspecified complicationsType 2 diabetes mellitus with other specified complicationsType 2 diabetes mellitus without complicationsType 2 diabetes mellitus with multiple complications
Data source
- Registry
- Sri Lanka Clinical Trials Registry
- Trial ID
- SLCTR_2011_008
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for SLCTR_2011_008 through Pure Global AI's free database. This Phase 3 trial is sponsored by Boehringer Ingelheim India Pvt Ltd and is currently status unknown. The study focuses on Diabetes Mellitus, Type 2.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Sri Lanka Clinical Trials Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.